# Ayuh Ventures

> Ayuh Ventures is a VC fund backing Health Care and Biotechnology. See 10 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Total investments: 10
- Last investment: Jun 2025
- Lead investor: 0%
- Last updated: Aug 2026
- Website: http://www.ayuh.vc

Ayuh Ventures is an early stage longevity fund investing in technologies focused on addressing mental health, neurological disorders, inflammatory diseases, sexual & reproductive health, and aging

## Contacts

5 contacts available for Ayuh Ventures. Shizune tracks 1 team members at Ayuh Ventures. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/ayuh-ventures?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Seed | $5M–$12M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 7 | 70% |
| Biotechnology | 5 | 50% |
| Therapeutics | 3 | 30% |
| Pharmaceutical | 3 | 30% |
| Medical | 2 | 20% |

17 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 4 | 40% |
| Pre-Seed | 2 | 20% |
| Series A | 1 | 10% |
| Series B | 1 | 10% |
| Convertible Note | 1 | 10% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 6 | 60% |
| United Kingdom | 2 | 20% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Kunal Sethi | General Partner | 0 | https://shizune.co/investors/profile/kunal-sethi |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Samphire Neuroscience | Samphire Neuroscience builds clinically validated neurotechnology to support women across their lives. Our wearable devices, Nettle™ and Lutea™, are built on the same underlying brain-stimulation technology, targeting neural pathways involved in pain, mood, stress, and sleep regulation. - Lutea™ is available globally as a wellness device. Itstimulates the same regions of the brain to support stress regulation, sleep, and recovery - key drivers of readiness and long-term performance - allowing athletes and teams to move beyond wellbeing education alone to practical, evidence-based intervention. - Nettle™ is a CE-marked (EU and UK regulated), drug- and hormone-free device that has been clinically shown to improve pain, mood, functionality, and the ability to train during the menstrual cycle, with measurable benefits after one month of use - supporting athletes to maintain training intensity and movement quality during their period. - The Samphire App is the platform controlling all Samphire hardware products with the use of CycleSync™ AI technology: the only one of its kind to support personalized neurotechnology use for women. | $5M | Seed | Jun 03, 2025 |  |
| Samphire Neuroscience | Samphire Neuroscience builds clinically validated neurotechnology to support women across their lives. Our wearable devices, Nettle™ and Lutea™, are built on the same underlying brain-stimulation technology, targeting neural pathways involved in pain, mood, stress, and sleep regulation. - Lutea™ is available globally as a wellness device. Itstimulates the same regions of the brain to support stress regulation, sleep, and recovery - key drivers of readiness and long-term performance - allowing athletes and teams to move beyond wellbeing education alone to practical, evidence-based intervention. - Nettle™ is a CE-marked (EU and UK regulated), drug- and hormone-free device that has been clinically shown to improve pain, mood, functionality, and the ability to train during the menstrual cycle, with measurable benefits after one month of use - supporting athletes to maintain training intensity and movement quality during their period. - The Samphire App is the platform controlling all Samphire hardware products with the use of CycleSync™ AI technology: the only one of its kind to support personalized neurotechnology use for women. | $2.3M | Pre-Seed | Feb 21, 2024 |  |
| Samphire Neuroscience | Samphire Neuroscience builds clinically validated neurotechnology to support women across their lives. Our wearable devices, Nettle™ and Lutea™, are built on the same underlying brain-stimulation technology, targeting neural pathways involved in pain, mood, stress, and sleep regulation. - Lutea™ is available globally as a wellness device. Itstimulates the same regions of the brain to support stress regulation, sleep, and recovery - key drivers of readiness and long-term performance - allowing athletes and teams to move beyond wellbeing education alone to practical, evidence-based intervention. - Nettle™ is a CE-marked (EU and UK regulated), drug- and hormone-free device that has been clinically shown to improve pain, mood, functionality, and the ability to train during the menstrual cycle, with measurable benefits after one month of use - supporting athletes to maintain training intensity and movement quality during their period. - The Samphire App is the platform controlling all Samphire hardware products with the use of CycleSync™ AI technology: the only one of its kind to support personalized neurotechnology use for women. |  | Pre-Seed | Aug 24, 2022 |  |
| Kanna Health | Kanna Health is a preclinical stage company that is developing novel therapeutics based on kanna, also known as Sceletium tortuosum. Kanna is a medicinal succulent that has been used for centuries by the San hunter-gatherers of South Africa. | $3.8M | Convertible Note | May 15, 2022 |  |
| Gilgamesh Pharmaceuticals | Gilgamesh Pharmaceuticals focuses on developing therapeutics that target neuropsychiatric and central nervous system conditions using small molecules derived from research on psychedelic compounds. The company designs and tests compounds that aim to modulate brain pathways involved in mental health disorders while reducing hallucinogenic effects.Its pipeline includes drug candidates intended for conditions such as depression, anxiety, and substance use disorders. Gilgamesh Pharmaceuticals conducts preclinical and clinical studies to evaluate the safety, dosing, and efficacy of its compounds. The company integrates medicinal chemistry, neuroscience, and clinical research to support drug development and regulatory progression. |  | Series B | May 01, 2022 |  |
| Psy Therapeutics | Psy Therapeutics is discovering and developing novel medicines to improve the lives of people affected by central nervous system (CNS) disorders. The company focuses on anxiety, depression, and dementia to improve neuropsychiatric care. |  | Seed | Apr 05, 2022 |  |
| Reset Pharmaceuticals | Reset Pharma is a biotechnology company that focuses on the development and commercialization of novel psychedelic treatments for patients with life-threatening illnesses, including cancer. Its program focuses on psilocybin with psychotherapy for patients with cancer-related demoralization, anxiety, and depression. | $11.1M | Series A | Feb 16, 2022 |  |
| Mindstate Design Labs | Mindstate Design Labs is a clinical-stage AI neuroengineering platform developing novel psychoactive drug classes for psychiatric disease indications. The company's Osmanthus ensemble of AI models maps the molecular biology of human emotional and cognitive states by integrating the world’s largest datasets of psychoactive pharmacology andsubjective experience. Mindstate's lead program MSD-001 received FDA and EMA approval for Phase I human trials in 2024.Mindstate Design Labs is a Y Combinator company backed by Initialized Capital and other top-tier investors including the founders of OpenAI, Neuralink, Coinbase, Instacart, AngelList, Twitch, and IVADO. The company was founded by biotech venture investor & serial operator Dillan DiNardo and by computer scientist & evolutionary biologist Dr. Thomas Ray, who is famous for instantiating biological phenomena in emergent machine learning systems. | $11.5M | Seed | Feb 10, 2022 |  |
| Clerkenwell Health | Clerkenwell Health is an innovative mental health company offering clinical research support services and psychedelic-assisted therapies. By providing independent psychedelic-specialist CRO services, Clerkenwell will accelerate the adoption of these treatments across Europe. The team are passionate about putting patients at the centre ofclinical trial design and delivering gold standard therapy protocols. |  | Pre-Seed | Feb 01, 2022 |  |
| Lief Therapeutics | Lief Therapeutics is a medical device developer whose goal is to revolutionize at-home care for post-traumatic stress disorder, depression, and anxiety. The device teaches users how to control the body's natural stress response through vibratory biofeedback exercises, allowing them to measure heart rate and breath with medical accuracy inorder to control stress. |  | Seed | Jul 15, 2021 |  |

10 of 10 investments shown.

## Co-investors
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund, 6 deals together
- [Seaside Ventures](https://shizune.co/investors/profile/seaside-ventures) — VC Fund, 4 deals together
- [AfterWork Ventures](https://shizune.co/investors/profile/afterwork-ventures) — VC Fund, 2 deals together
- [Empath Ventures](https://shizune.co/investors/profile/empath-ventures) — VC Fund, 2 deals together
- [FIRSTPICK](https://shizune.co/investors/profile/firstpick) — VC Fund, 2 deals together
- [SOSV HAX](https://shizune.co/investors/profile/hax-accelerator) — VC Fund, 2 deals together

## Similar investors

### Similar industry
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

### Similar country
- [SFC Capital](https://shizune.co/investors/profile/startup-funding-club) — VC Fund
- [Fuel Ventures](https://shizune.co/investors/profile/fuel-ventures-fund) — VC Fund
- [Business Growth Fund](https://shizune.co/investors/profile/business-growth-fund) — VC Fund

## Featured in investor lists
- [Fitness VC Funds in United Kingdom](https://shizune.co/investors/fitness-vc-funds-united-kingdom)

## FAQ

### What does Ayuh Ventures invest in?

Ayuh Ventures invests primarily in Health Care, Biotechnology and Therapeutics startups, most often at Seed and Pre-Seed stage. Most of the 10 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Ayuh Ventures's check size?

Ayuh Ventures typically joins rounds of $5M–$12M at Seed. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Ayuh Ventures participates in.

### How do I contact Ayuh Ventures?

Public channels for Ayuh Ventures include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Ayuh Ventures?

The team at Ayuh Ventures includes Kunal Sethi (General Partner). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co